

ACRUX DEFERS RELEASE OF FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2016

Acrux (ASX: ACR) will defer release of its financial results for the year ended 30 June 2016. The Company's results will be filed in accordance with requirements under the *Corporations Act* and ASX listing rules.

The investor conference call, scheduled on Wednesday 10 August at 11am, will be deferred until the financial results are released. Acrux will release details of the rescheduled call in due course.

For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

Sharon Papworth, CFO and Company Secretary: 03 8379 0100

About Acrux

Acrux (ASX: ACR) is a drug development company focused on commercialising topical products using its proprietary drug delivery technology. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and licensed a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Acrux will continue to innovate and bring its developed products to the market in collaboration with licensees.

For further information on Acrux, visit www.acrux.com.au

